EGFR and neoplasm: Moreover, resistance is commonly associated with the use of EGFR inhibitors in cancer patients in clinic.16 Therefore, strategies for blocking additional signaling critical for tumor growth likely lead to enhanced anti-tumor responses and reduced tumor resistance.